Search Results 1031-1040 of 17040 for monoclonal antibody

1. Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia - Mayo Clinic

   ... antibody therapy within 42 days of registration; patients may have ... Monoclonal antibodies must not have been received for 1 week prior to registration; ...

2. A Study of Pembrolizumab Alone as Therapy for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1; Prior chemotherapy, targeted ...

3. Stereotactic Body Radiotherapy Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a ...

4. Biomarker-guided CNI substitution in Kidney Transplantation Assessment - Mayo Clinic

   anti-Tumor necrosis factor(TNF) Monoclonal antibodies (mAb), or Belatacept, abatacept, ... Positive for a Donor Specific Antibody (DSA) 0-6 months post-kidney ...

5. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

   Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1. High risk of developing thromboembolic events, who are unwilling to take ...

6. A Study of the Effectiveness and Safety of Pembrolizumab (MK-3475) for Women with Advanced Recurrent Ovarian Cancer - Mayo Clinic

   Has had prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to the planned ...

7. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 ...

8. A Study to Evaluate Tazemetostat Combined with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma - Mayo Clinic

   ... antibody must be negative for HCV RNA by PCR to be eligible for study participation ... Monoclonal and/or bispecific antibodies or CAR T - At least 28 days. 5 ...

9. Clinical trials - Oncology (Medical)

   A Study of Hematopoiesis in Patients with Monoclonal ... Monoclonal B Cell Lymphocytosis (MBL) and B ... antibodies) treatment, CPI-naïve hepatocellular ...

10. A Study to Evaluate RVT-1401 for the Treatment of Patients with Active, Moderate-to-severe Graves' Ophthalmopathy - Mayo Clinic

    Use of rituximab, tocilizumab, or any monoclonal antibody/Fc-fusion biologic for immunomodulation within the past 9 months prior to Baseline. Use of ...